Background
The long-term oncologic outcome of robotic surgery for thyroid cancer is not well
established. The aim of this study was to predict the long-term oncologic outcome
of robotic surgery by using dynamic risk stratification in classic papillary thyroid
carcinoma.
Methods
A total of 444 propensity score–matched pairs of patients with papillary thyroid carcinoma
treated with robotic surgery and conventional open surgery were classified into 4
response-to-therapy categories. The results were compared between the robotic surgery
and open surgery groups.
Results
The median follow-up duration was 60 months. After propensity score matching, the
robotic surgery group showed less extensive thyroid surgery and lymph node dissection
and a higher proportion of patients who underwent radioactive iodine remnant ablation
than the open surgery group; however, the dynamic risk stratification did not differ
between the 2 groups (P = .086).
Conclusion
The long-term oncologic outcome of robotic surgery is expected to be comparable with
that of open surgery based on the dynamic risk stratification.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Safety of robotic thyroidectomy approaches: Meta-analysis and systematic review.Head Neck. 2014; 36: 137-143
- Robotic thyroidectomy versus nonrobotic approaches: A meta-analysis examining surgical outcomes.Surg Innov. 2016; 23: 317-325
- A systematic review and meta-analysis comparing surgically-related complications between robotic-assisted thyroidectomy and conventional open thyroidectomy.Ann Surg Oncol. 2014; 21: 850-861
- Robotic thyroidectomy versus conventional open thyroidectomy for thyroid cancer: A systematic review and meta-analysis.Surg Endosc. 2017; 31: 3985-4001
- Surgical safety and oncologic effectiveness in robotic versus conventional open thyroidectomy in thyroid cancer: A systematic review and meta-analysis.Ann Surg Oncol. 2015; 22: 3022-3032
- Robotic thyroidectomy versus conventional open thyroidectomy for differentiated thyroid cancer: Meta-analysis.J Laryngol Otol. 2015; 129: 558-567
- Early surgical outcomes of robotic thyroidectomy by a gasless unilateral axillo-breast or axillary approach for papillary thyroid carcinoma: 2 years' experience.Head Neck. 2012; 34: 617-625
- Oncologic outcomes of robotic thyroidectomy: 5-year experience with propensity score matching.Surg Endosc. 2016; 30: 4785-4792
- Technical and oncologic safety of robotic thyroid surgery.Ann Surg Oncol. 2013; 20: 1927-1933
- Update on differentiated thyroid cancer staging.Endocrinol Metab Clin North Am. 2014; 43: 401-421
- A risk-adapted approach to follow-up in differentiated thyroid cancer.Rambam Maimonides Med J. 2016; 7https://doi.org/10.5041/RMMJ.10231
- Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.Thyroid. 2010; 20: 1341-1349
- Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.Eur J Endocrinol. 2014; 170: 23-30
- Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine.J Clin Endocrinol Metab. 2016; 101: 2692-2700
- Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy.Thyroid. 2017; 27: 524-530
- Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.Eur J Endocrinol. 2011; 165: 441-446
- AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma.Anticancer Res. 2003; 23: 4283-4288
- Staging systems for papillary thyroid carcinoma: A review and comparison.Ann Surg. 2007; 245: 366-378
- Strategies of radioiodine ablation in patients with low-risk thyroid cancer.N Engl J Med. 2012; 366: 1663-1673
- Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.Clin Endocrinol. 2008; 69: 659-663
- Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.Eur J Endocrinol. 2013; 169: 689-693
- The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM.Ann Surg Oncol. 2010; 17: 1471-1474
- Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.Nucl Med Commun. 2011; 32: 954-959
- Long-term oncologic outcome of robotic versus open total thyroidectomy in PTC: A case-matched retrospective study.Surg Endosc. 2016; 30: 3474-3479
- Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: Is there a role for serum thyroglobulin measurement?.J Clin Endocrinol Metab. 2012; 97: 2748-2753
- Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2005; 90: 1440-1445
- Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2008; 93: 4683-4689
- Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.N Engl J Med. 2012; 366: 1674-1685
- The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: A meta-analysis involving 3947 patients.J Clin Endocrinol Metab. 2012; 97: 2754-2763
- Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.Thyroid. 2013; 23: 1401-1407
Article info
Publication history
Published online: September 13, 2018
Accepted:
July 31,
2018
Received in revised form:
July 10,
2018
Received:
April 24,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
